PHARMACOKINETICS OF ATRACURIUM METABOLITES
نویسندگان
چکیده
منابع مشابه
Pharmacokinetics of atracurium and its metabolites.
The pharmacokinetic profile of atracurium was studied in normal patients and in patients with renal failure, renal-hepatic failure, or hepatic disease. Its short elimination half-life was not significantly altered by renal failure, but in patients with severe liver disease elimination of its metabolites was prolonged, necessitating care during long-term i.v. infusions in patients with hepatic d...
متن کاملPharmacokinetics of atracurium.
Sir,—We congratulate Drs Beetner, Bjorksten and Crankshaw on their description of the pharmacokinetics of atracurium [1]. As they observe correctly, the derivation of pharmacokinetic parameters after a single bolus dose is subject to difficulties because of the presumed degradation of atracurium in sites peripheral to the plasma. In our view, however, the crucial flaw in previous attempts to de...
متن کاملPharmacokinetics of atracurium and laudanosine in patients with hepatic cirrhosis.
The pharmacokinetic profiles of atracurium and one of its derivatives, laudanosine were studied following an i.v. bolus of atracurium 0.6 mg kg-1 administered to eight patients with hepatic cirrhosis and to seven healthy controls. The central volume of distribution of atracurium was greater in the patients with cirrhosis (104.6 ml kg-1) compared with the controls (69.6 ml kg-1) (P less than 0.0...
متن کاملPharmacokinetics of alkylresorcinol metabolites in human urine.
Wholegrain cereals are reported to promote beneficial health effects. Wholegrain wheat and rye are almost exclusive sources of alkylresorcinols, and intact alkylresorcinols together with their plasma and urinary metabolites, 3-(3,5-dihydroxyphenyl)-1-propanoic acid (DHPPA) and 3,5-dihydroxybenzoic acid (DHBA), have been proposed as biomarkers of the intake of these foods in humans. The pharmaco...
متن کاملPharmacokinetics and pharmacodynamics of pentoxifylline and metabolites
Pentoxifylline increases erythrocyte flexibility, reduces blood viscosity,and inhibits platelet aggregation and is thus used in the treatment of peripheral vasculardisease. It is transformed into at least seven phase I metabolites, of which two, M1 andM5, are active. The reduction of the keto group of pentoxifylline to a secondary alcoholin M1 takes place chiefly in erythrocytes...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Anaesthesia
سال: 1988
ISSN: 0007-0912
DOI: 10.1093/bja/60.4.477-b